Acrivon Therapeutics, Inc.

    • Market Cap $206.40M
    • PE -3
    • Debt $NaN
    • Cash $43.61M
    • EV $NaN
    • FCF -$63.77M

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$76.98M
    EBIT-$85.30M
    ROE-39%
    ROA-40%
    FCF-$63.77M
    Equity$196.89M
    Growth Stability1
    PE-2.68
    PB1.05
    P/FCF-3.24
    Price/Cash0.21
    Equity CAGR3%
    Earnings Growth YoY55%
    Earnings Growth QoQ19%
    Equity CAGR 5Y3%
    Equity CAGR 3Y6%
    Market Cap$206.40M
    Assets$214.68M
    Cash$43.61M
    Shares Outstanding31.13M
    Working Capital174.17M
    Current Ratio12.75
    Shares Growth 3y1%
    Equity Growth QoQ-9%
    Equity Growth YoY43%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.

    SEC Filings

    Direct access to Acrivon Therapeutics, Inc. (ACRV) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2022
      • 10-K Dec 31
      • 10-Q Sep 30

    Sector Comparison

    How does Acrivon Therapeutics, Inc. compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Acrivon Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Acrivon Therapeutics, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Acrivon Therapeutics, Inc..

    = -$638M
    012345678910TV
    fcf-$64M-$64M-$64M-$64M-$64M-$64M-$64M-$64M-$64M-$64M-$64M-$638M
    DCF-$58M-$53M-$48M-$44M-$40M-$36M-$33M-$30M-$27M-$25M-$246M
    Value-$638M

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/202112/202212/2023TTM
    Net Margins----
    ROA--18%-49%-40%
    ROE--18%-50%-39%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/202112/202212/2023TTM
    Debt over FCF----
    Debt over Equity----
    Growth Stability---1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/202112/202212/2023CAGR 5Y
    Revenue YoY growth----
    Earnings YoY growth-92%94%-
    Equity YoY growth--816%-29%3%
    FCF YoY growth-127%36%-